Background: Adnexal masses are a frequent cause of patient complications that necessitate diagnostic imaging, surgical intervention, and postoperative pathology. No large-scale clinical investigation had previously explored the wide variation in GI-diagnostic RADS's performance among trials. Objective: The aim of the current study was to highlight the role of Gynecological Reporting Data System (GIRADS) and Ovarian Reporting Data System (ORADS) in differentiating ovarian lesions and determine which of them a higher accuracy has based on biopsy result and short interval follow up. Patients and methods: A cross-sectional study was conducted on 100 female patients with ovarian mass, attending at Radiodiagnosis Department of Zagazig University Hospitals from March 2020 to March 2021. Results: With an AUC of 0.983, 100% sensitivity, 96% specificity, 82% positive predictive value (PPV), 100% negative predictive value (NPV), and 97% accuracy, GIRAD can distinguish between benign and malignant lesions. ORAD has a high area under the curve (AUC) for distinguishing between benign and malignant lesions; its sensitivity is 92.9%, specificity is 91.9%, PPV is 65%, and NPV is 98.8%. Kappa (κ) = 0.834 indicates moderate agreement between GIRAD and ORAD in determining whether lesions are benign or malignant. Conclusion: Clinical decision-making appears to be aided by the GI-RADS categorization of adnexal masses, in comparison to the GIRADS, the ORADS classification system for ovarian masses is a useful non-invasive diagnostic tool with excellent sensitivity in differentiating between benign and malignant neoplastic lesions. When compared to the ORADS simple rules, the GIRADS was more sensitive while maintaining equivalent specificity as well as reliability.